©DANIEL ROUSSELOT/Sanofi

Sanofi and GSK will Provide up to 300 Million doses of COVID-19 vaccine to the European Union

Originally published on sanofi.com.

Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union

  • Agreement signed today supports scale-up of manufacturing capabilities in several European countries
  • Vaccine candidate uses Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system

Sanofi and GSK finalized and signed today an Advanced purchase agreement with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine, once the vaccine is approved. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology. This final agreement confirms the announcement made on July 31 by both companies and marks a key milestone in protecting European populations against COVID-19.

The contract will allow the purchase of a vaccine against COVID-19 for all Member States of the European Union (EU), which may donate reserved doses to lower- and middle-income countries. The EU will provide upfront funding to support the scale-up of Sanofi and GSK manufacturing capabilities on European soil. The antigen and final vaccine doses will be manufactured in European countries, leveraging Sanofi and GSK’s industrial sites in Belgium, Italy, Germany and France.

The Companies announced the launch of its Phase 1/2 clinical study in support of the vaccine’s development on September 3rd. A Phase 3 study is planned to begin by the end of 2020 and regulatory approval could be requested in the first half of 2021. Thanks in part to the agreement signed today, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant with the intent to produce up to one billion doses per year overall to help meet high and urgent demand for vaccines worldwide.

Sanofi and GSK are working worldwide in the fight against COVID-19

Elsewhere, Sanofi and GSK recently signed agreements with the United States where they have longstanding partnerships with the Biomedical Advanced Research and Development Authority, and also with the UK Government. The partners  plan to provide a significant portion of total worldwide available supply capacity to the global initiative “Access to COVID‐19 Tools (ACT) Accelerator,” a global collaboration of leaders of governments, global health organizations, businesses and philanthropies to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

On the front lines in the fight against COVID-19

In addition to the recombinant protein-based vaccine in collaboration with GSK, Sanofi is developing a messenger RNA (mRNA) vaccine in partnership with Translate Bio. With several innovative vaccine platforms currently being investigated across the industry, mRNA is considered among the most promising. Preclinical data have shown that two immunizations of the mRNA vaccine induced high neutralizing antibody levels that are comparable to the upper range of those observed in infected humans. Sanofi expects the Phase 1/2 study to start in November, with earliest potential approval in the second half of 2021. Translate Bio has established mRNA vaccine manufacturing capacity and Sanofi expects to be able to supply annual capacity of 90 to 360 million doses.

Latest News

economics workforce

Economics Field Is ‘Too White’ and ‘Too Male’ According to Top Federal Reserve Policymakers

Top Federal Reserve officials from a dozen regional banks met on April 13 to discuss the racial-disparity problem within the world of economics. According to Christopher Rugaber of The Associated Press, “top Federal Reserve policymakers on Tuesday underscored their concern that Black and Hispanic people are sharply underrepresented in the…

NCAA

NCAA Declares Full Support of Transgender Athletes; Pledges Its Events Will Be ‘Free of Discrimination’

In a blow to a growing number of states considering harsh and discriminatory bans on transgender rights, the National Collegiate Athletic Association has publicly come out in support of diversity and inclusion — backing transgender rights and saying that it will no longer hold championship events in locations that aren’t…

Black homeownership grows

Home Ownership Among Black Americans Increased Significantly in 2020 — But Rates Still Lag Dramatically Behind Whites

While the COVID-19 pandemic struck all Americans, Black men and women took the biggest hit, suffering greater levels of unemployment, poverty, food insecurity and even death from the virus than other races. But while all this was happening, something interesting and unexpected took place as well — homeownership for Blacks,…

Will Smith

Will Smith and Apple Pull Upcoming Film Out of Georgia In Protest of Racist Voter Suppression Law

The fallout from Georgia Gov. Brian Kemp’s decision to sign the most racist and restrictive voter suppression bill in the U.S. continues. First, Major League Baseball moved its upcoming All-Star game from Atlanta to Denver. Then, corporations ranging from Delta to Coca-Cola blasted the state and declared the bill as…

Caron Nazario

Virginia Police Pull-Over, Threaten and Pull Gun on Black Army Lieutenant Because They ‘Missed’ New Purchase Paperwork on Truck He Was Driving

In the latest of a seemingly never-ending stream of cases involving police racism and organizational misbehavior, two police officers in Virginia have been accused of threatening a Black Army lieutenant — and pulling a gun on him — during a routine traffic stop involving vehicle identification. David K. Li of…

Georgia voter suppression protests

More Than 100 Corporate CEOs Discuss Ways to Fight Against Georgia Voter Suppression Law

On Saturday, April 10, the CEOs from dozens of the country’s leading corporations came together on Zoom to talk about ways Corporate America can aid in the fight against a number of controversial and racist voter suppression laws that are currently in discussion across the U.S., including the new law…